Global Travel Vaccines Market Size Study, by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, Recombinant Vector Vaccines, Subunit Vaccines, Toxoid Vaccines), by Disease (DPT, Hepatitis A, Hepatitis B, Japanese Encephalitis, Measles and Mumps, Meningococcal, Rabies, Typhoid, Varicella, Yellow Fever), and Regional Forecasts 2024-2032
Global Travel Vaccines Market is valued at approximately USD 8.26 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.06% over the forecast period 2024-2032. Travel vaccines are essential immunizations recommended or required for international travelers based on specific regional disease risks. These vaccines play a crucial role in preventing diseases that may be prevalent in certain parts of the world, thus safeguarding travelers' health and contributing to global public health efforts. The continuous growth in international travel, coupled with rising awareness about vaccine-preventable diseases, fuels the demand for travel vaccines. Governmental travel regulations mandating certain vaccines for entry further bolster the market. The global tourism industry's expansion and proactive health measures by travelers also drive the need for travel vaccines. Furthermore, advancements in vaccine storage and stability technologies enhance accessibility and distribution, contributing significantly to market growth.
Despite the promising growth, the travel vaccines market faces several challenges, including high costs associated with vaccine development and stringent regulatory requirements, which can lead to prolonged approval times. Additionally, the limited shelf life of vaccines, the need for cold chain logistics, and vaccine hesitancy among certain traveler demographics can impede market growth. However, developing vaccines against emerging infectious disease threats and expanding the travel vaccine portfolio to include neglected tropical diseases present substantial opportunities. Increased public-private partnerships for vaccine research and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders further enhance market prospects.
The cryopreserved amniotic membrane segment is witnessing significant growth due to its live cell therapy applications. The cryopreserved amniotic membrane is preserved at subzero temperatures, maintaining its biological properties and structural integrity. This preservation method ensures the tissue's therapeutic effectiveness, allowing for long-term storage and availability for various clinical applications. Similarly, lyophilization amniotic membranes, produced by freeze-drying the tissue, offer stability at room temperature, facilitating easy storage and distribution.
In terms of application, the use of amniotic membranes in ophthalmology is highly recognized for treating complex ocular surface diseases. Their therapeutic properties, including promoting surface reconstruction and reducing inflammation, make them essential in corneal surgeries. Amniotic membranes also serve as biological dressings in surgical wound care, assisting with the natural healing process in burns, chronic wounds, and surgical incisions. Specialized clinics utilize these membranes for targeted treatments in dental, ophthalmology, and dermatology practices.
The hospital segment is a significant end-user of amniotic membranes, utilizing them in various surgical procedures to leverage their regenerative properties. Ambulatory Surgical Centers (ASCs) also implement amniotic membrane transplants, particularly in ophthalmology, wound care, and reconstructive surgery. Research centers and laboratories focus on exploring novel uses and enhancing the medical understanding of amniotic membranes, primarily studying their biocompatibility, preservation methods, and therapeutic potential.
The key regions considered for the global Travel Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Travel Vaccines Market in terms of revenue. The market growth in the region is being attributed to factors including increasing travel and healthcare investments, high outbound travel rates and robust healthcare infrastructure in the United States and Canada. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising investments in smart technologies and extensive vaccine research and development.
Major market players included in this report are:
Abbott Laboratories
AstraZeneca PLC
Bavarian Nordic A/S
Bharat Biotech Ltd.
Bio-Manguinhos
Bio-Med (P) Limited
Biological E Limited
Cadila Pharmaceuticals Limited
CSL Limited
Dano Vaccines & Biologicals Private Limited
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Incepta Pharmaceuticals Ltd.
Indian Immunologicals Ltd.
The detailed segments and sub-segment of the market are explained below:
By Type:
North America
Despite the promising growth, the travel vaccines market faces several challenges, including high costs associated with vaccine development and stringent regulatory requirements, which can lead to prolonged approval times. Additionally, the limited shelf life of vaccines, the need for cold chain logistics, and vaccine hesitancy among certain traveler demographics can impede market growth. However, developing vaccines against emerging infectious disease threats and expanding the travel vaccine portfolio to include neglected tropical diseases present substantial opportunities. Increased public-private partnerships for vaccine research and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders further enhance market prospects.
The cryopreserved amniotic membrane segment is witnessing significant growth due to its live cell therapy applications. The cryopreserved amniotic membrane is preserved at subzero temperatures, maintaining its biological properties and structural integrity. This preservation method ensures the tissue's therapeutic effectiveness, allowing for long-term storage and availability for various clinical applications. Similarly, lyophilization amniotic membranes, produced by freeze-drying the tissue, offer stability at room temperature, facilitating easy storage and distribution.
In terms of application, the use of amniotic membranes in ophthalmology is highly recognized for treating complex ocular surface diseases. Their therapeutic properties, including promoting surface reconstruction and reducing inflammation, make them essential in corneal surgeries. Amniotic membranes also serve as biological dressings in surgical wound care, assisting with the natural healing process in burns, chronic wounds, and surgical incisions. Specialized clinics utilize these membranes for targeted treatments in dental, ophthalmology, and dermatology practices.
The hospital segment is a significant end-user of amniotic membranes, utilizing them in various surgical procedures to leverage their regenerative properties. Ambulatory Surgical Centers (ASCs) also implement amniotic membrane transplants, particularly in ophthalmology, wound care, and reconstructive surgery. Research centers and laboratories focus on exploring novel uses and enhancing the medical understanding of amniotic membranes, primarily studying their biocompatibility, preservation methods, and therapeutic potential.
The key regions considered for the global Travel Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Travel Vaccines Market in terms of revenue. The market growth in the region is being attributed to factors including increasing travel and healthcare investments, high outbound travel rates and robust healthcare infrastructure in the United States and Canada. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising investments in smart technologies and extensive vaccine research and development.
Major market players included in this report are:
Abbott Laboratories
AstraZeneca PLC
Bavarian Nordic A/S
Bharat Biotech Ltd.
Bio-Manguinhos
Bio-Med (P) Limited
Biological E Limited
Cadila Pharmaceuticals Limited
CSL Limited
Dano Vaccines & Biologicals Private Limited
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Incepta Pharmaceuticals Ltd.
Indian Immunologicals Ltd.
The detailed segments and sub-segment of the market are explained below:
By Type:
- Attenuated Vaccines
- Conjugate Vaccines
- DNA Vaccines
- Inactive Vaccines
- Recombinant Vector Vaccines
- Subunit Vaccines
- Toxoid Vaccines
- DPT
- Hepatitis A
- Hepatitis B
- Japanese Encephalitis
- Measles and Mumps
- Meningococcal
- Rabies
- Typhoid
- Varicella
- Yellow Fever
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- ROE
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Brazil
- Mexico
- RoLA
- Saudi Arabia
- South Africa
- RoMEA
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL TRAVEL VACCINES MARKET EXECUTIVE SUMMARY
1.1. Global Travel Vaccines Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Disease
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL TRAVEL VACCINES MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL TRAVEL VACCINES MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increased International Travel
3.1.2. Rising Awareness About Vaccine-Preventable Diseases
3.1.3. Governmental Travel Regulations
3.2. Market Challenges
3.2.1. High Costs of Vaccine Development
3.2.2. Strict Regulatory Requirements
3.2.3. Cold Chain Logistics
3.3. Market Opportunities
3.3.1. Development of Vaccines for Emerging Infectious Diseases
3.3.2. Expansion of Travel Vaccine Portfolio
3.3.3. Public-Private Partnerships for Vaccine R&D
CHAPTER 4. GLOBAL TRAVEL VACCINES MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY TYPE 2022-2032
5.1. Segment Dashboard
5.2. Global Travel Vaccines Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Attenuated Vaccines
5.2.2. Conjugate Vaccines
5.2.3. DNA Vaccines
5.2.4. Inactive Vaccines
5.2.5. Recombinant Vector Vaccines
5.2.6. Subunit Vaccines
5.2.7. Toxoid Vaccines
CHAPTER 6. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY DISEASE 2022-2032
6.1. Segment Dashboard
6.2. Global Travel Vaccines Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. DPT
6.2.2. Hepatitis A
6.2.3. Hepatitis B
6.2.4. Japanese Encephalitis
6.2.5. Measles and Mumps
6.2.6. Meningococcal
6.2.7. Rabies
6.2.8. Typhoid
6.2.9. Varicella
6.2.10. Yellow Fever
CHAPTER 7. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY REGION 2022-2032
7.1. North America Travel Vaccines Market
7.1.1. U.S. Travel Vaccines Market
7.1.1.1. Type breakdown size & forecasts, 2022-2032
7.1.1.2. Disease breakdown size & forecasts, 2022-2032
7.1.2. Canada Travel Vaccines Market
7.2. Europe Travel Vaccines Market
7.2.1. U.K. Travel Vaccines Market
7.2.2. Germany Travel Vaccines Market
7.2.3. France Travel Vaccines Market
7.2.4. Spain Travel Vaccines Market
7.2.5. Italy Travel Vaccines Market
7.2.6. Rest of Europe Travel Vaccines Market
7.3. Asia-Pacific Travel Vaccines Market
7.3.1. China Travel Vaccines Market
7.3.2. India Travel Vaccines Market
7.3.3. Japan Travel Vaccines Market
7.3.4. Australia Travel Vaccines Market
7.3.5. South Korea Travel Vaccines Market
7.3.6. Rest of Asia Pacific Travel Vaccines Market
7.4. Latin America Travel Vaccines Market
7.4.1. Brazil Travel Vaccines Market
7.4.2. Mexico Travel Vaccines Market
7.4.3. Rest of Latin America Travel Vaccines Market
7.5. Middle East & Africa Travel Vaccines Market
7.5.1. Saudi Arabia Travel Vaccines Market
7.5.2. South Africa Travel Vaccines Market
7.5.3. Rest of Middle East & Africa Travel Vaccines Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Abbott Laboratories
8.1.2. AstraZeneca PLC
8.1.3. Bavarian Nordic A/S
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. AstraZeneca PLC
8.3.3. Bavarian Nordic A/S
8.3.4. Bharat Biotech Ltd.
8.3.5. Bio-Manguinhos
8.3.6. Bio-Med (P) Limited
8.3.7. Biological E Limited
8.3.8. Cadila Pharmaceuticals Limited
8.3.9. CSL Limited
8.3.10. Dano Vaccines & Biologicals Private Limited
8.3.11. Dynavax Technologies Corporation
8.3.12. Emergent BioSolutions Inc.
8.3.13. GlaxoSmithKline PLC
8.3.14. Incepta Pharmaceuticals Ltd.
8.3.15. Indian Immunologicals Ltd.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
1.1. Global Travel Vaccines Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Disease
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL TRAVEL VACCINES MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL TRAVEL VACCINES MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increased International Travel
3.1.2. Rising Awareness About Vaccine-Preventable Diseases
3.1.3. Governmental Travel Regulations
3.2. Market Challenges
3.2.1. High Costs of Vaccine Development
3.2.2. Strict Regulatory Requirements
3.2.3. Cold Chain Logistics
3.3. Market Opportunities
3.3.1. Development of Vaccines for Emerging Infectious Diseases
3.3.2. Expansion of Travel Vaccine Portfolio
3.3.3. Public-Private Partnerships for Vaccine R&D
CHAPTER 4. GLOBAL TRAVEL VACCINES MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY TYPE 2022-2032
5.1. Segment Dashboard
5.2. Global Travel Vaccines Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Attenuated Vaccines
5.2.2. Conjugate Vaccines
5.2.3. DNA Vaccines
5.2.4. Inactive Vaccines
5.2.5. Recombinant Vector Vaccines
5.2.6. Subunit Vaccines
5.2.7. Toxoid Vaccines
CHAPTER 6. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY DISEASE 2022-2032
6.1. Segment Dashboard
6.2. Global Travel Vaccines Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. DPT
6.2.2. Hepatitis A
6.2.3. Hepatitis B
6.2.4. Japanese Encephalitis
6.2.5. Measles and Mumps
6.2.6. Meningococcal
6.2.7. Rabies
6.2.8. Typhoid
6.2.9. Varicella
6.2.10. Yellow Fever
CHAPTER 7. GLOBAL TRAVEL VACCINES MARKET SIZE & FORECASTS BY REGION 2022-2032
7.1. North America Travel Vaccines Market
7.1.1. U.S. Travel Vaccines Market
7.1.1.1. Type breakdown size & forecasts, 2022-2032
7.1.1.2. Disease breakdown size & forecasts, 2022-2032
7.1.2. Canada Travel Vaccines Market
7.2. Europe Travel Vaccines Market
7.2.1. U.K. Travel Vaccines Market
7.2.2. Germany Travel Vaccines Market
7.2.3. France Travel Vaccines Market
7.2.4. Spain Travel Vaccines Market
7.2.5. Italy Travel Vaccines Market
7.2.6. Rest of Europe Travel Vaccines Market
7.3. Asia-Pacific Travel Vaccines Market
7.3.1. China Travel Vaccines Market
7.3.2. India Travel Vaccines Market
7.3.3. Japan Travel Vaccines Market
7.3.4. Australia Travel Vaccines Market
7.3.5. South Korea Travel Vaccines Market
7.3.6. Rest of Asia Pacific Travel Vaccines Market
7.4. Latin America Travel Vaccines Market
7.4.1. Brazil Travel Vaccines Market
7.4.2. Mexico Travel Vaccines Market
7.4.3. Rest of Latin America Travel Vaccines Market
7.5. Middle East & Africa Travel Vaccines Market
7.5.1. Saudi Arabia Travel Vaccines Market
7.5.2. South Africa Travel Vaccines Market
7.5.3. Rest of Middle East & Africa Travel Vaccines Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Abbott Laboratories
8.1.2. AstraZeneca PLC
8.1.3. Bavarian Nordic A/S
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. AstraZeneca PLC
8.3.3. Bavarian Nordic A/S
8.3.4. Bharat Biotech Ltd.
8.3.5. Bio-Manguinhos
8.3.6. Bio-Med (P) Limited
8.3.7. Biological E Limited
8.3.8. Cadila Pharmaceuticals Limited
8.3.9. CSL Limited
8.3.10. Dano Vaccines & Biologicals Private Limited
8.3.11. Dynavax Technologies Corporation
8.3.12. Emergent BioSolutions Inc.
8.3.13. GlaxoSmithKline PLC
8.3.14. Incepta Pharmaceuticals Ltd.
8.3.15. Indian Immunologicals Ltd.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Travel Vaccines market, report scope
TABLE 2. Global Travel Vaccines market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Travel Vaccines market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 4. Global Travel Vaccines market estimates & forecasts by Disease 2022-2032 (USD Billion)
TABLE 5. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Travel Vaccines market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Travel Vaccines market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
…..
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
TABLE 1. Global Travel Vaccines market, report scope
TABLE 2. Global Travel Vaccines market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Travel Vaccines market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 4. Global Travel Vaccines market estimates & forecasts by Disease 2022-2032 (USD Billion)
TABLE 5. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Travel Vaccines market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Travel Vaccines market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Travel Vaccines market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Travel Vaccines market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Travel Vaccines market estimates & forecasts by segment 2022-2032 (USD Billion)
…..
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
LIST OF FIGURES
FIG 1. Global Travel Vaccines market, research methodology
FIG 2. Global Travel Vaccines market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Travel Vaccines market, key trends 2023
FIG 5. Global Travel Vaccines market, growth prospects 2022-2032
FIG 6. Global Travel Vaccines market, porters 5 force model
FIG 7. Global Travel Vaccines market, PESTEL analysis
FIG 8. Global Travel Vaccines market, value chain analysis
FIG 9. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Travel Vaccines market, regional snapshot 2022 & 2032
FIG 15. North America Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 16. Europe Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 18. Latin America Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 20. Global Travel Vaccines market, company market share analysis (2023)
…..
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
FIG 1. Global Travel Vaccines market, research methodology
FIG 2. Global Travel Vaccines market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Travel Vaccines market, key trends 2023
FIG 5. Global Travel Vaccines market, growth prospects 2022-2032
FIG 6. Global Travel Vaccines market, porters 5 force model
FIG 7. Global Travel Vaccines market, PESTEL analysis
FIG 8. Global Travel Vaccines market, value chain analysis
FIG 9. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Travel Vaccines market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Travel Vaccines market, regional snapshot 2022 & 2032
FIG 15. North America Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 16. Europe Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 18. Latin America Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Travel Vaccines market 2022 & 2032 (USD Billion)
FIG 20. Global Travel Vaccines market, company market share analysis (2023)
…..
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
